Tech Center 1600 • Art Units: 1621 1625
This examiner grants 58% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18015671 | CYCLIC CYANOENONE DERIVATIVES AS MODULATORS OF KEAP1 | Non-Final OA | MERCK SHARP & DOHME LLC |
| 18013380 | METHODS AND INTERMEDIATES FOR PREPARING JAK INHIBITORS | Non-Final OA | Sun Pharmaceutical Industries, Inc. |
| 18333039 | METAL-ASSISTED DELAYED FLUORESCENT EMITTERS EMPLOYING PYRIDO-PYRROLO-ACRIDINE AND ANALOGUES | Final Rejection | Arizona Board of Regents on behalf of Arizona State University |
| 17132937 | DONOR-ACCEPTOR TYPE STABLE THERMALLY ACTIVATED DELAYED FLUORESCENT MATERIALS BASED ON RIGID MOLECULAR STRUCTURE DESIGN | Final Rejection | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY |
| 16885467 | Novel method of treating dystonia | Final Rejection | KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY |
| 18256548 | FLOW SYNTHESIS OF RDX | Non-Final OA | BAE SYSTEMS plc |
| 18287897 | Therapeutics for Hyponatremia and Polycystic Kidney Disease | Non-Final OA | University of Cincinnati |
| 18232230 | CHIRAL PHOSPHORIC ACIDS IMMOBILIZED ON SOLID SUPPORT FOR THE SELECTIVE PROTECTION OF HYDROXYL GROUPS | Non-Final OA | REGENTS OF THE UNIVERSITY OF MICHIGAN |
| 18005161 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | Non-Final OA | SUMITOMO CHEMICAL COMPANY, LIMITED |
| 18161380 | Heteroatom-Containing Silane Compound | Non-Final OA | Henkel AG & Co. KGaA |
| 17774763 | SUBSTITUTED THIAZOLE AROMATIC RING-BASED COMPOUND AND PREPARATION METHOD THEREFOR, HERBICIDAL COMPOSITION AND USE THEREOF | Non-Final OA | QINGDAO KINGAGROOT CHEMICAL COMPOUND CO., LTD. |
| 18555058 | COMBINATION THERAPY COMPRISING A PKC INHIBITOR AND A MEK INHIBITOR | Non-Final OA | PFIZER, INC. |
| 17916484 | INDOLE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | Non-Final OA | Vertex Pharmaceuticals Incorporated |
| 18608369 | ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY | Final Rejection | Chugai Seiyaku Kabushiki Kaisha |
| 17757389 | METHOD FOR PRODUCING DIMETHYL TEREPHTHALATE FROM POLYESTER METHANOLYSIS DEPOLYMERIZATION SYSTEMS | Final Rejection | Eastman Chemical Company |
| 18565704 | PHARMACEUTICAL PREPARATION FOR PREVENTING OR TREATING PULMONARY FIBROSIS | Non-Final OA | J2H BIOTECH INC. |
| 18555291 | TEAD INHIBITORS | Non-Final OA | ORION CORPORATION |
| 18013696 | OXADIAZOLE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Non-Final OA | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES |
| 18276269 | Tricyclic Derivatives Useful As PARP7 Inhibitors | Non-Final OA | JACOBIO PHARMACEUTICALS CO., LTD. |
| 18276342 | PRODRUG COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Non-Final OA | MINGHUI PHARMACEUTICAL (SHANGHAI) LIMITED |
| 18264468 | ARYL ETHER COMPOUNDS AS TEAD MODULATORS | Non-Final OA | Merck Sharp& Dohme LLC |
| 18040962 | COMPLEMENT FACTOR B INHIBITOR, AND PHARMACEUTICAL COMPOSITION, PREPARATION METHOD AND USE THEREOF | Non-Final OA | SHANGHAI MEIYUE BIOTECH DEVELOPMENT CO. LTD |
| 18265191 | BROAD SPECTRUM ANTIVIRAL COMPOUNDS TARGETING THE SKI COMPLEX | Non-Final OA | UNIVERSITY OF MARYLAND, BALTIMORE |
| 17999179 | PROCESS OF PREPARING BUTYL-(5S)-5-({2-[4-(BUTOXYCARBONYL)PHENYL]ETHYL}[2-(2-{[3-CHLORO-4'-(TRIFLUOROMETHYL)[BIPHENYL]-4-YL]METHOXY}PHENYL)ETHYL]AMINO)-5,6,7,8-TETRAHYDROQUINOLINE-2-CARBOXYLATE | Non-Final OA | BAYER PHARMA AKTIENGESELLSCHAFT |
| 18257773 | MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 | Non-Final OA | ACADIA Pharmaceuticals Inc. |
| 17774263 | PROCESS TO CONTINUOUSLY PREPARE A CYCLIC CARBONATE | Final Rejection | NEW GREEN WORLD B.V. |
| 18017939 | MANUFACTURING OF DIMERIC CONTRAST AGENTS | Non-Final OA | BRACCO IMAGING S.P.A. |
| 18089265 | PROCESSES AND INTERMEDIATES FOR THE PREPARATIONS OF CARBOPROST AND CARBOPROST TROMETHAMINE, AND CARBOPROST TROMETHAMINE PREPARED THEREFROM | Final Rejection | CHIROGATE INTERNATIONAL INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy